KALA BIO Past Earnings Performance
Past criteria checks 0/6
KALA BIO has been growing earnings at an average annual rate of 9.6%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been declining at an average rate of 2.6% per year.
Key information
9.6%
Earnings growth rate
30.0%
EPS growth rate
Biotechs Industry Growth | 11.5% |
Revenue growth rate | -2.6% |
Return on equity | -562.4% |
Net Margin | n/a |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How KALA BIO makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -42 | 21 | 19 |
30 Sep 23 | 0 | -46 | 22 | 17 |
30 Jun 23 | 0 | -9 | 26 | 17 |
31 Mar 23 | 3 | -26 | 44 | 17 |
31 Dec 22 | 4 | -45 | 65 | 18 |
30 Sep 22 | 6 | -80 | 83 | 17 |
30 Jun 22 | 8 | -137 | 99 | 14 |
31 Mar 22 | 9 | -145 | 104 | 13 |
31 Dec 21 | 11 | -143 | 105 | 12 |
30 Sep 21 | 12 | -126 | 108 | 12 |
30 Jun 21 | 11 | -126 | 106 | 13 |
31 Mar 21 | 9 | -113 | 93 | 16 |
31 Dec 20 | 6 | -104 | 81 | 18 |
30 Sep 20 | 5 | -95 | 69 | 21 |
30 Jun 20 | 5 | -90 | 60 | 25 |
31 Mar 20 | 6 | -91 | 62 | 26 |
31 Dec 19 | 6 | -94 | 65 | 27 |
30 Sep 19 | 5 | -98 | 65 | 30 |
30 Jun 19 | 3 | -90 | 58 | 30 |
31 Mar 19 | 1 | -81 | 48 | 31 |
31 Dec 18 | 0 | -67 | 35 | 29 |
30 Sep 18 | 0 | -53 | 26 | 26 |
30 Jun 18 | 0 | -47 | 20 | 26 |
31 Mar 18 | 0 | -44 | 15 | 27 |
31 Dec 17 | 0 | -42 | 11 | 29 |
30 Sep 17 | 0 | -39 | 7 | 30 |
30 Jun 17 | 0 | -39 | 6 | 31 |
31 Mar 17 | 0 | -38 | 8 | 29 |
31 Dec 16 | 0 | -33 | 8 | 25 |
30 Sep 16 | 0 | -30 | 7 | 22 |
30 Jun 16 | 0 | -25 | 8 | 16 |
31 Mar 16 | 0 | -18 | 5 | 13 |
31 Dec 15 | 0 | -17 | 5 | 11 |
30 Sep 15 | 0 | -17 | 4 | -2 |
30 Jun 15 | 0 | -17 | 4 | -1 |
31 Mar 15 | 0 | -18 | 4 | -1 |
31 Dec 14 | 0 | -19 | 4 | 0 |
31 Dec 13 | 0 | -11 | 3 | 0 |
Quality Earnings: 0JQ2 is currently unprofitable.
Growing Profit Margin: 0JQ2 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0JQ2 is unprofitable, but has reduced losses over the past 5 years at a rate of 9.6% per year.
Accelerating Growth: Unable to compare 0JQ2's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0JQ2 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: 0JQ2 has a negative Return on Equity (-562.35%), as it is currently unprofitable.